Current Report Filing (8-k)
October 29 2020 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): October 28, 2020
THERALINK
TECHNOLOGIES, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
|
000-52218
|
|
20-2590810
|
|
(State
or other jurisdiction
|
|
(Commission
|
|
(I.R.S.
Employer
|
|
of incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
15000
W. 6th Ave., #400
Golden,
CO 80401
(Address
of principal executive offices)
(888)
585-4923
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act: None
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [X]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
|
Item
7.01
|
Regulation
FD Disclosure.
|
Theralink
Technologies, Inc. (the “Company”) has made available an Investor Presentation, which is attached to this Current
Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
This
information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by
specific reference in such filing.
|
Item
9.01
|
Financial
Statements and Exhibits
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
THERALINK
TECHNOLOGIES, INC.
|
|
|
|
|
|
By:
|
/s/
Mick Ruxin
|
|
|
Name:
|
Mick
Ruxin, M.D.
|
|
|
Title:
|
Chief
Executive Officer
|
|
|
|
|
|
Date:
October 29, 2020
|
|
|